{"id":9404,"date":"2025-12-28T22:22:42","date_gmt":"2025-12-28T13:22:42","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4534\/"},"modified":"2026-08-23T12:55:51","modified_gmt":"2026-08-23T03:55:51","slug":"company-4534","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4534\/","title":{"rendered":"MOCHIDA PHARMACEUTICAL CO"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4534","DATE":"2025-12-26","longName":"Mochida Pharmaceutical Co., Ltd.","company_name_ja":"","fullTimeEmployees":1479,"address":"","phone":"","website":"https:\/\/www.mochida.co.jp","industry":"Drug Manufacturers - Specialty & Generic","sector":"Healthcare","regularMarketPrice":3445,"financialCurrency":"","marketCap":122126,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":222.96000000000001,"epsForward":0,"bookValue":0,"totalRevenue":116951000000,"OperatingIncome":10147000000,"operatingMargins":8.6799999999999997,"NetIncome":7903000000,"profitMargins":6.7599999999999998,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":5.6299999999999999,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T04:42:17.718267\", \"ticker\": \"4534\", \"ticker_full\": \"4534.T\", \"company_name\": \"MOCHIDA PHARMACEUTICAL CO\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": null, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 3120.0, \"high\": null, \"low\": null, \"mean\": null, \"median\": null}, \"earnings_dates\": {\"has_data\": true, \"next_earnings\": null, \"future_count\": 0, \"past_earnings\": [{\"date\": \"2016-01-31\", \"eps_estimate\": 101.11, \"eps_actual\": 90.22, \"surprise_pct\": -10.78}, {\"date\": \"2015-07-30\", \"eps_estimate\": 43.46, \"eps_actual\": 80.56, \"surprise_pct\": 85.36}, {\"date\": \"2015-05-14\", \"eps_estimate\": 28.84, \"eps_actual\": 26.65, \"surprise_pct\": -7.6}, {\"date\": \"2015-01-29\", \"eps_estimate\": 63.24, \"eps_actual\": 84.87, \"surprise_pct\": 34.2}, {\"date\": \"2014-10-30\", \"eps_estimate\": 76.62, \"eps_actual\": 29.29, \"surprise_pct\": -61.77}]}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 36.25, \"institution_pct\": 14.11, \"major_holders\": [{\"label\": \"\", \"value\": 36.25}, {\"label\": \"\", \"value\": 14.11}, {\"label\": \"\", \"value\": 22.13}, {\"label\": \"\", \"value\": 69.0}], \"institutional_holders\": [{\"holder\": \"Vanguard International Stock Index-Total Intl Stock Indx\", \"shares\": 324658, \"date_reported\": \"2024-07-31\", \"pct_held\": 0.87, \"pct_change\": 0.0, \"value\": 1012932960}, {\"holder\": \"Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund\", \"shares\": 193862, \"date_reported\": \"2024-09-30\", \"pct_held\": 0.52, \"pct_change\": 0.0, \"value\": 604849440}, {\"holder\": \"iShares Core MSCI EAFE ETF\", \"shares\": 134900, \"date_reported\": \"2024-09-30\", \"pct_held\": 0.36, \"pct_change\": 0.0, \"value\": 420888000}, {\"holder\": \"iShares MSCI EAFE Small Cap ETF\", \"shares\": 66800, \"date_reported\": \"2024-09-30\", \"pct_held\": 0.18, \"pct_change\": -1.62, \"value\": 208416000}, {\"holder\": \"Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index\", \"shares\": 63900, \"date_reported\": \"2024-07-31\", \"pct_held\": 0.17, \"pct_change\": 9.42, \"value\": 199368000}, {\"holder\": \"iShares Core MSCI Total International Stock ETF\", \"shares\": 62800, \"date_reported\": \"2024-09-30\", \"pct_held\": 0.17, \"pct_change\": 0.0, \"value\": 195936000}, {\"holder\": \"DFA Japanese Small Company Series\", \"shares\": 51698, \"date_reported\": \"2024-07-31\", \"pct_held\": 0.14, \"pct_change\": -23.97, \"value\": 161297760}, {\"holder\": \"DFA International Core Equity Portfolio\", \"shares\": 52098, \"date_reported\": \"2024-07-31\", \"pct_held\": 0.14, \"pct_change\": 10.15, \"value\": 162545760}, {\"holder\": \"Schwab Strategic Tr-Schwab Fundamental Intl Small Company Idx ETF\", \"shares\": 51012, \"date_reported\": \"2024-08-31\", \"pct_held\": 0.14, \"pct_change\": -5.89, \"value\": 159157440}, {\"holder\": \"Schwab Strategic Tr-Schwab International Small Cap Equity ETF\", \"shares\": 43625, \"date_reported\": \"2024-08-31\", \"pct_held\": 0.12, \"pct_change\": -1.12, \"value\": 136110000}], \"mutualfund_holders\": []}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker; Dinagest, an agent for endometriosis, adenomyosis, and dysmenorrhea; Lexapro, an antidepressant; Tamcet, an analgesic for chronic pain; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Heparin Sodium MOCHIDA anticoagulant agents. The company also develops mesalazine for the treatment of ulcerative colitis; tocilizumab for the treatment of rheumatoid arthritis; dotinurad for the treatment of gout and hyperuricemia; dienogest formulation for dysmenorrhea; treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and icosapent for hypertriglyceridemia. In addition, it develops medical devices, including dMD-001 that is used for the treatment of articular cartilage lesions; dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for post-operative adhesion. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":40,"get_dividend_history_year2":80,"get_dividend_history_year3":80,"get_dividend_history_year4":80,"get_dividend_history_year5":90,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T02:49:43.130258\", \"ticker\": \"4534\", \"ticker_full\": \"4534.T\", \"company_name\": \"MOCHIDA PHARMACEUTICAL CO\", \"company_info\": {\"name_en\": \"MOCHIDA PHARMACEUTICAL CO\", \"long_name\": \"Mochida Pharmaceutical Co., Ltd.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - Specialty & Generic\", \"website\": \"https:\/\/www.mochida.co.jp\", \"employees\": 1479, \"country\": \"Japan\", \"city\": \"Tokyo\", \"address\": \"7, Yotsuya 1-chome\", \"description\": \"Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker; Dinagest, an agent for endometriosis, adenomyosis, and dysmenorrhea; Lexapro, an antidepressant; Tamcet, an analgesic for chronic pain; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Heparin Sodium MOCHIDA anticoagulant agents. The company also develops mesalazine for the treatment of ulcerative colitis; tocilizumab for the treatment of rheumatoid arthritis; dotinurad for the treatment of gout and hyperuricemia; dienogest formulation for dysmenorrhea; treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and icosapent for hypertriglyceridemia. In addition, it develops medical devices, including dMD-001 that is used for the treatment of articular cartilage lesions; dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for post-operative adhesion. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 3235.0, \"deviation\": 0.77, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 3183.2, \"deviation\": 2.41, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 3242.07, \"deviation\": 0.55, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 3387.83, \"deviation\": -3.77, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 116951000000.0, \"revenue_fmt\": \"\u00a51170\u5104\", \"gross_profit\": 56260000000.0, \"gross_profit_fmt\": \"\u00a5563\u5104\", \"operating_income\": 10147000000.0, \"operating_income_fmt\": \"\u00a5101\u5104\", \"ebit\": 11243000000.0, \"ebit_fmt\": \"\u00a5112\u5104\", \"net_income\": 7903000000.0, \"net_income_fmt\": \"\u00a579\u5104\", \"eps\": 222.96, \"operating_margin\": 8.68, \"total_assets\": 182720000000.0, \"total_assets_fmt\": \"\u00a51827\u5104\", \"total_equity\": 140324000000.0, \"total_equity_fmt\": \"\u00a51403\u5104\", \"total_debt\": 10000000000.0, \"total_debt_fmt\": \"\u00a5100\u5104\", \"total_cash\": 28064000000.0, \"total_cash_fmt\": \"\u00a5281\u5104\", \"equity_ratio\": 76.8, \"de_ratio\": 0.07, \"current_ratio\": 4.29, \"operating_cf\": -7350000000.0, \"operating_cf_fmt\": \"-\u00a574\u5104\", \"investing_cf\": -16848000000.0, \"investing_cf_fmt\": \"-\u00a5168\u5104\", \"financing_cf\": 7033000000.0, \"financing_cf_fmt\": \"\u00a570\u5104\", \"free_cf\": -10045000000.0, \"free_cf_fmt\": \"-\u00a5100\u5104\", \"net_margin\": 6.76, \"roe\": 5.63, \"roa\": 4.33}, {\"year\": 2025, \"revenue\": 105159000000.0, \"revenue_fmt\": \"\u00a51052\u5104\", \"gross_profit\": 53787000000.0, \"gross_profit_fmt\": \"\u00a5538\u5104\", \"operating_income\": 8126000000.0, \"operating_income_fmt\": \"\u00a581\u5104\", \"ebit\": 8055000000.0, \"ebit_fmt\": \"\u00a581\u5104\", \"net_income\": 5685000000.0, \"net_income_fmt\": \"\u00a557\u5104\", \"eps\": 160.36, \"operating_margin\": 7.73, \"total_assets\": 160121000000.0, \"total_assets_fmt\": \"\u00a51601\u5104\", \"total_equity\": 130693000000.0, \"total_equity_fmt\": \"\u00a51307\u5104\", \"total_debt\": 0.0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 45154000000.0, \"total_cash_fmt\": \"\u00a5452\u5104\", \"equity_ratio\": 81.62, \"de_ratio\": 0.0, \"current_ratio\": 4.81, \"operating_cf\": 9354000000.0, \"operating_cf_fmt\": \"\u00a594\u5104\", \"investing_cf\": 17355000000.0, \"investing_cf_fmt\": \"\u00a5174\u5104\", \"financing_cf\": -2865000000.0, \"financing_cf_fmt\": \"-\u00a529\u5104\", \"free_cf\": 7194000000.0, \"free_cf_fmt\": \"\u00a572\u5104\", \"net_margin\": 5.41, \"roe\": 4.35, \"roa\": 3.55}, {\"year\": 2024, \"revenue\": 102885000000.0, \"revenue_fmt\": \"\u00a51029\u5104\", \"gross_profit\": 52070000000.0, \"gross_profit_fmt\": \"\u00a5521\u5104\", \"operating_income\": 5803000000.0, \"operating_income_fmt\": \"\u00a558\u5104\", \"ebit\": 6162000000.0, \"ebit_fmt\": \"\u00a562\u5104\", \"net_income\": 4547000000.0, \"net_income_fmt\": \"\u00a545\u5104\", \"eps\": 126.8, \"operating_margin\": 5.64, \"total_assets\": 158800000000.0, \"total_assets_fmt\": \"\u00a51588\u5104\", \"total_equity\": 127965000000.0, \"total_equity_fmt\": \"\u00a51280\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 33290000000.0, \"total_cash_fmt\": \"\u00a5333\u5104\", \"equity_ratio\": 80.58, \"de_ratio\": 0.0, \"current_ratio\": 4.47, \"operating_cf\": -7480000000.0, \"operating_cf_fmt\": \"-\u00a575\u5104\", \"investing_cf\": 74000000.0, \"investing_cf_fmt\": \"\u00a574.0M\", \"financing_cf\": -6393000000.0, \"financing_cf_fmt\": \"-\u00a564\u5104\", \"free_cf\": -9776000000.0, \"free_cf_fmt\": \"-\u00a598\u5104\", \"net_margin\": 4.42, \"roe\": 3.55, \"roa\": 2.86}, {\"year\": 2023, \"revenue\": 103261000000.0, \"revenue_fmt\": \"\u00a51033\u5104\", \"gross_profit\": 55114000000.0, \"gross_profit_fmt\": \"\u00a5551\u5104\", \"operating_income\": 8507000000.0, \"operating_income_fmt\": \"\u00a585\u5104\", \"ebit\": 9044000000.0, \"ebit_fmt\": \"\u00a590\u5104\", \"net_income\": 6649000000.0, \"net_income_fmt\": \"\u00a566\u5104\", \"eps\": 178.93, \"operating_margin\": 8.24, \"total_assets\": 158831000000.0, \"total_assets_fmt\": \"\u00a51588\u5104\", \"total_equity\": 126773000000.0, \"total_equity_fmt\": \"\u00a51268\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 47010000000.0, \"total_cash_fmt\": \"\u00a5470\u5104\", \"equity_ratio\": 79.82, \"de_ratio\": 0.0, \"current_ratio\": 4.31, \"operating_cf\": 7297000000.0, \"operating_cf_fmt\": \"\u00a573\u5104\", \"investing_cf\": -2949000000.0, \"investing_cf_fmt\": \"-\u00a529\u5104\", \"financing_cf\": -6884000000.0, \"financing_cf_fmt\": \"-\u00a569\u5104\", \"free_cf\": 5131000000.0, \"free_cf_fmt\": \"\u00a551\u5104\", \"net_margin\": 6.44, \"roe\": 5.24, \"roa\": 4.19}, {\"year\": 2022, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 0, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [{\"year\": 2022, \"amount\": 90.0}, {\"year\": 2023, \"amount\": 80.0}, {\"year\": 2024, \"amount\": 80.0}, {\"year\": 2025, \"amount\": 80.0}, {\"year\": 2026, \"amount\": 40.0}], \"latest\": 40.0, \"has_data\": true}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-9404","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MOCHIDA PHARMACEUTICAL CO - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4534\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4534\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4534\/\",\"name\":\"MOCHIDA PHARMACEUTICAL CO - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2025-12-28T13:22:42+00:00\",\"dateModified\":\"2026-08-23T03:55:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4534\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4534\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4534\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MOCHIDA PHARMACEUTICAL CO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MOCHIDA PHARMACEUTICAL CO - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4534\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4534\/","url":"https:\/\/japanir.jp\/en\/company\/company-4534\/","name":"MOCHIDA PHARMACEUTICAL CO - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2025-12-28T13:22:42+00:00","dateModified":"2026-08-23T03:55:51+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4534\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4534\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4534\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"MOCHIDA PHARMACEUTICAL CO"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/9404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=9404"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=9404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}